Novartis Investigative site

Cambridge CB7 5JD

4 studies enrolling now · 33 studies all time

What they study most

ANCA Associated Vasculitis (AAV), Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Advanced NET of GI Origin, Advanced NET of Lung Origin, Ankylosing Spondylitis, Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, Carcinoma, Renal Cell, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Cystic Fibrosis, Gastrointestinal Stromal Tumor (GIST), Healthy Volunteers, Pulmonary Arterial Hypertension

Studies at this site

• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — Recruiting now
• A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease — Recruiting now
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer — Recruiting now
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA — Recruiting now
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients — Running, not enrolling
• Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis — Running, not enrolling
• Iptacopan in Patients With ANCA Associated Vasculitis — Running, not enrolling
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — Completed
• Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment — Running, not enrolling
• Post-Authorization Long-Term Safety Study of LUTATHERA — Running, not enrolling
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma — Completed
• Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC — Stopped early
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
• A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients — Completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis — Completed
• Extension in AS: Sustainability of Benefits, Safety and Tolerability — Completed
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia — Stopped early
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures — Completed
• 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis — Completed
• Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET — Stopped early
• A Study of Nilotinib Versus Imatinib in GIST Patients — Completed
• Imatinib (QTI571) in Pulmonary Arterial Hypertension — Completed
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia — Completed
• Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis — Completed
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE